News & Events
Genetic Analysis: Launch of GA-map® Discovery – A microbiome profiling offering for Research Customers (opens in a new tab)
OSLO, NORWAY – 24 October 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the Company launches the GA-map® Discovery – a new microbiome profiling service offering directed to research customers in the academia and microbiome industry. The GA-map® Discovery is GA’s first dedi…
Seres Therapeutics to Highlight VOWST™ Data at IDWeek (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 12, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced multiple abstracts to be presented at IDWeek 2023 in Boston, Massachusetts ( October 11-15, 2023 ), including two posters of post-hoc analyses from the ECOSPOR III and ECOSPOR IV Phase 3…
Genetic Analysis: Development project initiated for a new companion diagnostic test (opens in a new tab)
OSLO, NORWAY – 12 October 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has successfully completed a pilot project and initiated a development project in collaboration with a global pharmaceutical company to develop a new microbiome-based rapid companion* diagnostic …
Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023 (opens in a new tab)
Poster presentations include mechanistic data from VE303 Phase 2 CONSORTIUM study that explore how VE303 prevents recurrence of Clostridioides difficile (C. diff) infection A novel defined bacterial consortium, VE707 suppresses carriage of multidrug-resistant organisms (MDRO) in vivo and in vitro Phase 3 pivotal study …
Vedanta Biosciences to Participate at Upcoming Investor Conferences (opens in a new tab)
CAMBRIDGE, MA – Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences: BMO Life Sciences Private Company Showcase Present…
Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation (opens in a new tab)
VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis First patient dosed in the global Phase 2 COLLECTiVE202 study CAMBRIDGE, Mass.–(BUSINESS WIRE)– Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral the…
Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Sep. 7, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 , at 12:15 p.m.…
Half-year report January–June 2023 (opens in a new tab)
OSLO, NORWAY, August 30, 2023 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the half-year report for the second quarter and first six months of 2023. The half-year report is available as an attached file to this release and on the Company’s website (www.genetic-analysis.com). Below is a summary of the …
Genetic Analysis AS ramps up its market presence for the GA-map® microbiome testing in the US (opens in a new tab)
The post Genetic Analysis AS ramps up its market presence for the GA-map® microbiome testing in the US appeared first on Genetic Analysis.…
New publication shows the benefits of the GA-map® testing platform in Diabetes Type 2 (opens in a new tab)
OSLO, NORWAY – 23 August 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that a scientific article has recently been published in the medical journal BMC Endocrine Disorders, showing promising results of using microbiota as a tool for risk prediction of diabetes disease at an early sta…
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (opens in a new tab)
– VOWST TM is the first orally administered microbiome therapeutic FDA-approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI (rCDI) – – VOWST early commercial uptake encouraging with strong initial demand observed across…
Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug. 1, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 , at 3:00 p.m. ET .…
Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug. 1, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 8, 2023 at 8:30 a.m. ET to discuss second quarter results and provide a…
MaaT Pharma Joins Microbiome Therapeutics Innovation Group (opens in a new tab)
WASHINGTON, July 20, 2023 /PRNewswire/ — The Microbiome Therapeutics Innovation Group (MTIG) today announced […]…
Genetic Analysis receives patent approval in South Africa (opens in a new tab)
OSLO, NORWAY – June 29, 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has been awarded a patent (2017/06307) by the South African Companies and Intellectual Property Commission (CIPC). The important patent entitled “A METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYS…
Seres Therapeutics Named to TIME100 Most Influential Companies List (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun. 21, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, has been named to the “TIME100 Most Influential Companies,” a list of 100 companies making an extraordinary impact around the world.…
Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023 (opens in a new tab)
– Post-hoc analysis results with VOWST highlight the importance of gut microbiome diversity as a critical component of a treatment regimen to reduce the risk of recurrent C. difficile infection in rCDI patients, regardless of the number of prior recurrences – CAMBRIDGE, Mass. & HOBOKEN, N.J.…
Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun. 9, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres Therapeutics management, will participate in a question and answer format discussion at the Goldman Sachs Global Healthcare Conference on…
Genetic Analysis AS enters an agreement with ELTA90 Group to distribute and launch GA-map® technology in the Balkan region (opens in a new tab)
The post Genetic Analysis AS enters an agreement with ELTA90 Group to distribute and launch GA-map® technology in the Balkan region appeared first on Genetic Analysis.…
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection (opens in a new tab)
– VOWST is now available by prescription in the U.S. for adult patients following antibiotic treatment for recurrent CDI – – VOWST Voyage™ Support Program to help reduce out-of-pocket patient costs for eligible patients and facilitate treatment start – CAMBRIDGE, Mass. & HOBOKEN, N.J.…